Our Network AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity Tags: #Cardiometabolic #Diabetes #Obesity #Partnership #AstraZeneca Global rights to Eccogene’s next-generation oral glucagon-like peptide 1 receptor agonist, ECC5004 as monotherapy and combination therapies.
